In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
暂无分享,去创建一个
K. Adams | G. Fonarow | T. LeJemtel | W. Abraham | M. Cheng | M. Costanzo | J. Wynne | R. Berkowitz
[1] J. Ornato,et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .
[2] J. Butler,et al. The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[3] U. Elkayam,et al. Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure. , 2004, The American journal of cardiology.
[4] G. Fonarow,et al. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. , 2003, Reviews in cardiovascular medicine.
[5] Christopher M O'Connor,et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. , 2003, Journal of the American College of Cardiology.
[6] T. LeJemtel,et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. , 2002, American heart journal.
[7] J. Tu,et al. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. , 2002, Archives of internal medicine.
[8] Robert M Califf,et al. Early statin initiation and outcomes in patients with acute coronary syndromes. , 2002, JAMA.
[9] Daniel Levy,et al. Long-term trends in the incidence of and survival with heart failure. , 2002, The New England journal of medicine.
[10] A. Burger,et al. Intravenous nesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure. , 2002, The American journal of cardiology.
[11] James B. Young. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial , 2002 .
[12] R. Califf,et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. , 2002, JAMA.
[13] J. Ghali,et al. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. , 2002, Journal of the American College of Cardiology.
[14] E. Antman,et al. ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .
[15] M. Lauer,et al. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: A propensity analysis. , 2001, JAMA.
[16] C. O'connor,et al. Inotropic therapy for heart failure: an evidence-based approach. , 2001, American heart journal.
[17] M. Lauer,et al. Aspirin Use and All-Cause Mortality Among Patients Being Evaluated for Known or Suspected Coronary Artery Disease , 2001 .
[18] J. O’Connell,et al. The economic burden of heart failure , 2000, Clinical cardiology.
[19] Orton,et al. INTRAVENOUS NESIRITIDE, A NATRIURETIC PEPTIDE, IN THE TREATMENT OF DECOMPENSATED CONGESTIVE HEART FAILURE , 2000 .
[20] P. Rosenbaum,et al. Invited commentary: propensity scores. , 1999, American journal of epidemiology.
[21] R. Califf,et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). , 1999, American heart journal.
[22] H. Eiskjaer,et al. Renal effects of brain natriuretic peptide in patients with congestive heart failure. , 1999, Clinical science.
[23] R. D'Agostino. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. , 2005, Statistics in medicine.
[24] L. Stevenson. Inotropic therapy for heart failure. , 1998, The New England journal of medicine.
[25] P. Binkley,et al. Parenteral inotropic support for advanced congestive heart failure. , 1998, Progress in cardiovascular diseases.
[26] W. Abraham,et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. , 1998, Journal of cardiac failure.
[27] Donald Rubin,et al. Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.
[28] Y Wang,et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. , 1997, Archives of internal medicine.
[29] D. Heitjan,et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. , 1996, Circulation.
[30] D. Mancini,et al. Rationale for treatment of patients with chronic heart failure with adrenergic blockade. , 1996, JAMA.
[31] M. Dolgin,et al. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels , 1994 .
[32] H. Nawrath,et al. Pharmacology of bipyridine phosphodiesterase III inhibitors. , 1991, European journal of anaesthesiology. Supplement.
[33] Wolfgang Kruse,et al. Early Readmission of Elderly Patients with Congestive Heart Failure , 1991, Journal of the American Geriatrics Society.
[34] S. Gottlieb,et al. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. , 1987, The New England journal of medicine.
[35] T. LeJemtel,et al. Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure. , 1986, Journal of the American College of Cardiology.
[36] D. Baim,et al. Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. , 1986, Circulation.
[37] D. Rubin,et al. Reducing Bias in Observational Studies Using Subclassification on the Propensity Score , 1984 .
[38] Leo Breiman,et al. Classification and Regression Trees , 1984 .
[39] D. Rubin,et al. The central role of the propensity score in observational studies for causal effects , 1983 .